GE HealthCare announced significant expansions and innovations in its radiation oncology portfolio at the European Society for Therapeutic Radiology and Oncology (ESTRO) 2025 Congress in Vienna, Austria. The company plans to integrate advanced AI and MRI technologies to streamline and enhance radiation therapy processes, ultimately aiming to improve patient outcomes and increase the precision of cancer treatments. Cancer remains a leading cause of death globally, with nearly ten million deaths per year, according to the World Health Organization (WHO). However, early detection and treatment could save approximately one-third of these lives. GE HealthCare’s new initiatives are designed to address this challenge by providing cutting-edge tools and technologies to healthcare professionals. One of the key components of GE HealthCare’s expansion is the addition of Spectronic Medical AB’s software offerings to its portfolio. Spectronic, based in Helsingborg, Sweden, specializes in advanced image analysis solutions for radiation oncology. Their FDA 510(k) cleared and CE-marked MRI Planner software uses artificial intelligence to convert standard MR images of the brain, head-neck, and pelvis into synthetic CT images, essential for radiation treatment planning. This technology significantly reduces the time and complexity involved in preparing these images, thereby accelerating the transition from diagnosis to treatment. Dr. Carl Siversson, CEO of Spectronic Medical, emphasized the transformative potential of their MRI-only radiotherapy planning innovations. He stated, “Spectronic Medical was founded on the vision that advanced MRI and AI technologies can unlock entirely new possibilities in radiotherapy. Our collaboration with GE HealthCare will help bring these innovations to a broader global audience, supporting the evolution toward more precise, personalized, and accessible cancer care.” GE HealthCare further bolstered its radiation therapy capabilities with the U.S. FDA 510(k) clearance of MR Contour DL, a new AI model designed for organs at risk (OAR) segmentation. MR Contour DL utilizes deep learning algorithms to generate precise contours of 37 organs and structures in the head-neck and pelvic regions from standard 2D or 3D MR images. This AI-driven tool automates a process that was previously manual, enhancing efficiency, consistency, and accuracy in treatment planning. Kelly Londy, president and CEO of GE HealthCare’s MR business, highlighted the importance of this development: “We’re committed to advancing MR imaging capabilities in radiation therapy to deliver more accurate and precise care. The integration of Spectronic’s software and MR Contour DL into our portfolio supports our vision for an MR-based radiation oncology workflow, enabling high-precision treatment planning for patients worldwide.” Additionally, GE HealthCare unveiled updates to its Intelligent Radiation Therapy (iRT) solution, which manages radiation therapy workflows. The updated version includes enhanced features to incorporate MR and AI-driven workflows, addressing the increasing demand for MR-guided radiation therapy. These updates are expected to make the treatment process more efficient and reduce diagnostic time and workload. Dr. Ben Newton, general manager of Oncology at GE HealthCare, underscored the company’s commitment: “Cancer cases are expected to continue rising, but survival rates have been improving thanks to advancements in medical technologies, early detection, and better treatment protocols. Our new AI-enabled innovations and expanded radiation oncology portfolio are part of our ongoing efforts to drive survival trends upwards and improve patient care.” GE HealthCare’s strategic moves in radiation oncology reflect a broader industry trend towards leveraging AI and advanced imaging technologies to enhance cancer treatment. These technologies not only promise to improve the accuracy and efficiency of treatment planning but also to make personalized and accessible care a reality for a larger number of patients. Industry insiders commend GE HealthCare for its proactive approach and the potential of these innovations to transform radiation oncology practices globally. Founded over 125 years ago, GE HealthCare is a leading provider of healthcare solutions, with a focus on medical technology, pharmaceutical diagnostics, and AI-enabled solutions. The company has an annual revenue of $19.7 billion and employs around 53,000 people dedicated to advancing medical care. As one of the 2025 Fortune World’s Most Admired Companies, GE HealthCare continues to lead the charge in transforming healthcare through innovation and technology. For more information about GE HealthCare and their presence at ESTRO 2025, visit their website or follow them on social media platforms.